Early Diabetes Remission Following Tirzepatide-Based Combination Therapy in a Young Indian Adult with Recent-Onset Type 2 Diabetes: A Case Report

Le résumé fourni par la source

Tirzepatide has demonstrated potent glucose-lowering and weight-reduction effects; however, real-world remission data remain limited. We report a 28-year-old male with recent-onset type 2 diabetes mellitus and obesity who was treated with tirzepatide-based multimodal therapy. Baseline evaluation revealed a body weight of 90 kg, body mass index of 30.8 kg/m?, HbA1c of 6.69%, fasting plasma glucose of 164 mg/dL, and triglycerides of 328.2 mg/dL. Treatment included once-weekly tirzepatide (2.5 mg, titrated to 5 mg), metformin 1000 mg/day, dapagliflozin 10 mg/day, and structured lifestyle modification consisting of a calorie-restricted diet and regular physical exercise. At one month, body weight decreased by 6 kg. At three months, total weight reduction reached 11 kg, HbA1c improved to 5.02%, fasting plasma glucose normalized to 98 mg/dL, and triglycerides decreased to 97.5 mg/dL. Metformin and dapagliflozin were discontinued, while tirzepatide was continued. The patient achieved diabetes remission according to international consensus criteria. This case demonstrates that early aggressive tirzepatide-based therapy may induce remission in early-stage type 2 diabetes mellitus.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.